Research Nester’s recent market research analysis on “Huntington’s Disease Treatment Market: Global Demand Analysis & Opportunity Outlook 2037” delivers a detailed competitor’s analysis and a detailed overview of the global reverse factoring market in terms of market segmentation by drugs, type, distribution channel, and by region.
Rising Demands for Huntington’s Disease Care to Minimize Patient’s Side Effects to Promote Global Market Share of Huntington’s Disease Treatment Market
The increase in Huntington disease (HD) cases globally has raised the demands for advanced Huntington’s disease care. Improvements in dissemination of information regarding the disease and on disease care has enhanced the rates of patients actively seeking medical treatment to stymy the growth of HD. Advancements in the direct genetic test has improved the efficacy of finding the huntingtin gene. Early detection of huntingtin can forewarn a patient on reproduction as children of those with the gene develop a 50% chance of acquiring the disease.
https://www.researchnester.com/sample-request-6517
The advent of new drugs, such as deutetrabenazine (Austedo) has increased the demands for HD treatment and therapeutic care. Pharmaceutical companies are investing and research and the Huntington Disease Society in America has listed new therapies in pipeline that will boost HD treatment and care. In September 2024, the European Medicines Agency (EMA) agreed to review Prilenia Therapeutics application seeking the approval of pridopidine, i.e., an oral therapy for adults diagnosed with the disease. The rising number of clinical trails and approval applications for new drugs and therapies are a testament to the rapid market growth.
Growth Drivers:
- Increased global awareness on Huntington’s disease and its care
- Growing rates of clinical trails in new treatments for Huntington’s disease
Challenges:
Huntington’s disease treatment is long-term and cause financial constraints to patients without insurance coverage. This reduces the accessibility of HD treatments. Additionally, the lack of awareness also poses a major challenge to the market growth as some nations such as India are yet to include HD as a rare disease owing to lower prevalence rates. This can affect adequate investment in research.
By drugs, the Huntington’s disease treatment market is segmented into tetrabenazine, deutetrabenazine, and other drugs. The tetrabenazine segment registered the largest revenue share in 2024 and is estimated to increase its market share during the forecast period with a profitable CAGR. The segment’s growth is attributed to its long-standing presence as a treatment for chorea in HD. It was the first FDA approved drug to manage chorea and has set a firm hold in the market as a dominant segment.
By region, the North America Huntington’s disease treatment market is poised to register the highest revenue share by the end of 2037. North America has a high rate of HD diagnosis with a gradual increase in cases over the decades. This has boosted demands for HD treatment for afflicted patients. In July 2024, Ingrezza Sprinkle to treat chorea in adults with HD and the movement disorder tardive dyskinesia is now available in the U.S. in capsule form[AB2] .
This report also provides the existing competitive scenario of some of the key players of the market i.e., Teva Pharmaceuticals Industries Ltd., UniQure, Neurocrine Biosciences Ltd., Sage Therapeutics, WaVe Life Sciences, Azevan Pharmaceuticals, and others.
Access our detailed report at:
https://www.researchnester.com/reports/huntingtons-disease-treatment-market/6517
Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.
Contact for more Info:
AJ Daniel
Email: info@researchnester.com
U.S. Phone: +1 646 586 9123
U.K. Phone: +44 203 608 5919
